Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis.

J Neuberger, E Christensen, B Portmann, J Caballeria, J Rodes, L Ranek, N Tygstrup, R Williams

One hundred and eighty nine patients with primary biliary cirrhosis were entered into a double blind, placebo controlled randomised trial starting in January 1978 to assess the therapeutic value of d-penicillamine 1200 mg daily. Eighteen of the 98 patients receiving d-penicillamine and 22 of the 91 placebo treated patients died during the study. Thirty six per cent of those on d-penicillamine and 8% of those on placebo were withdrawn from the study. No difference in overall survival was noted between the two groups of patients whether the results were analysed for the entire period of observation or only during the period in which the patients were receiving therapy. The mortality rate of those receiving d-penicillamine in histological stage I to II, however, was one third of that of the placebo group although this difference did not reach statistical significance. Using the occurrence rate ratio as the statistical method of analysis, no effect of d-penicillamine was noted on any clinical, biochemical or histological features examined, except the serum alanine aminotransferase activity which was greater in those on active treatment. In this trial we have been unable to establish any therapeutic benefit from the drug.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Prince, M. I, Jones, D. E J (2000). Classic diseases revisited: Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad. Med. J. 76: 199-206 [Abstract] [Full Text]  
• Poupon, R. E., Poupon, R., Balkau, B., The UDCA-PBC Study Group, (1994). Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis. NEJM 330: 1342-1347 [Abstract] [Full Text]